Accuri Cytometers, a Baird Venture Partners Portfolio Company, Completes $6 Million Series E Financing

ANN ARBOR, MI, July 12, 2010
 
Accuri Cytometers, Inc., a world leader in providing life science researchers with easy-to-use, cost-effective flow cytometers, announced completion of a $6 million Series E preferred stock financing. The financing included current investors Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences, Flagship Ventures and the InvestMichigan! Program co-managed by Credit Suisse.

For more information please read the Accuri news release.